மார்டின் ஒஸ்த்ேர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மார்டின் ஒஸ்த்ேர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மார்டின் ஒஸ்த்ேர் Today - Breaking & Trending Today

Duchenne Muscular Dystrophy

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter s investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in. Read More. ....

United Kingdom , Debjit Chattopadhyay , Gbola Amusa , Morgan Stanley Matthew Harrison , Martin Auster , Brian Abrahams , Sarepta Progressmonday , Morgan Stanley , Why Wave Life Sciences Valuation Is Falling , Gene Therapy Program On Holdtuesday , Roche Partnership Derisks Sarepta Investor Concernstuesday , Wave Life Sciences Ltd , Credit Suisse , Drug Administration , Therapeutics Inc , Roche Holdings Ag Basel , Sarepta Therapeutics Inc , Solid Biosciences Inc , Health Care , Wave Life Sciences , Duchenne Muscular Dystrophy , Dosing Of Sarepta , Next Gen Eteplirsen Can Potentially Achieve Over , Biosciences Inc , Data Encouraging Solid Biosciences , Analyst Projects ,

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Flexion Therapeutics Inc (NASDAQ: FLXN)
Popular Searches
Operator
Good afternoon, ladies and gentlemen, and welcome to the Flexion Therapeutics Business Update Call. [Operator Instructions]
I will now turn the call over to Scott Young, Flexion s Vice President of Corporate Communications and Investor Relations.SPONSORED:
10 stocks we like better than Flexion Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market. ....

United States , Dana Flanders Guggenheim , Daniel Busby , Raymond James , Gary Nachman , Graig Suvannavejh , Michael Clayman , Dan Busby , Martin Auster , Elliot Wilbur Raymond James , David Arkowitz , Francois Brisebois , Dana Flanders , Francois Brisebois Oppenheimer , Elliot Wilbur , Scott Young , Mike Clayman , Graig Suvannavejh Goldman Sachs , Department Of Defense , Goldman Sachs , Credit Suisse , Veterans Administration , Motley Fool Flexion Therapeutics Inc , Corporate Communications , Flexion Therapeutics Inc , Call Transcript ,

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

United States , Dana Flanders Guggenheim , Daniel Busby , Raymond James , Gary Nachman , Graig Suvannavejh , Michael Clayman , Dan Busby , Martin Auster , Elliot Wilbur Raymond James , David Arkowitz , Francois Brisebois , Dana Flanders , Francois Brisebois Oppenheimer , Elliot Wilbur , Scott Young , Mike Clayman , Graig Suvannavejh Goldman Sachs , Corporate Communications , Department Of Defense , Goldman Sachs , Credit Suisse , Flexion Therapeutics Inc , Veterans Administration , Flexion Therapeutics Business Update , Vice President ,

Esperion Therapeutics Inc (ESPR) Q4 2020 Earnings Call Transcript

Esperion Therapeutics Inc (ESPR) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Esperion Therapeutics Inc (NASDAQ: ESPR)
Popular Searches
Operator
Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today s conference call may be recorded. I would now like to hand the conference call over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC fili ....

Rick Bartram , Daiichi Sankyo Europe , Sheldon Koenig , Derek Archila , Julian Harrison , Joseph Thome Cowen , Joseph Thome , Michael Yee , Richard Bartram , Tim Mayleben , Geoff Meacham , Olivia Brayer , America Merrill Lynch , Timothy Mayleben , Daiichi Sankyo , Martin Auster , Tom Shrader , Michael Yee Jefferies , Paul Choi , Company Update Conference Call , Esperion Therapeutics Inc , Goldman Sachs , Credit Suisse , Ben Church , Corporate Communications Investor Relations , Motley Fool Esperion Therapeutics Inc ,

Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript

Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Ironwood Pharmaceuticals Fourth Quarter and Full Year 2020 Investor Update Conference Call. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Meredith Kaya. Thank you. Please go ahead.
Meredith Kaya
Vice President, Investor Relations and Corporate Communications
Good morning, and thanks for joining us for our fourth quarter and full year 2020 investor update. Our press release crossed the wire this morning and can be found on our website.
Today s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. The discussion of these statements and risk factors is available on the current Safe Harbor statement slide as well as under the heading Risk Factors in our quarterly report on Form 10-Q for the quarter ended September 30, 2020 and i ....

Mike Shetzline , Mark Mallon , Gina Consylman , Michael Shetzline , Tom Mccourt , Martin Auster , Meredith Kaya , Thomas Mccourt , Ironwood Pharmaceuticals Fourth Quarter , Ironwood Pharmaceuticals Inc , Corporate Communications , Head Of Drug Development , Credit Suisse , Full Year , Update Conference , Investor Relations , Safe Harbor , Risk Factors , Chief Medical Officer , Vice President , Chief Financial , Medical Officer , Senior Vice President , குறி மல்லன் , டோம் ம்க்கொர்ட் , மார்டின் ஒஸ்த்ேர் ,